Neon Therapeutics inks $55 mln Series A

Neon Therapeutics has launched with $55 million in Series A funding. Third Rock Ventures led the round with participation from Clal Biotechnology Industries and Access Industries. Based in Cambridge, Massachusetts, Neon Therapeutics is an immuno-oncology company focused on treating cancer.


Rhythm Metabolic racks up $40 mln Series A

Boston-based Rhythm Metabolic, a subsidiary of Rhythm, has closed $40 million in Series A funding. The investors included OrbiMed, Deerfield Management, Wellington Management Company, MPM Capital, New Enterprise Associates, Third Rock Ventures, Pfizer Ventures and Ipsen. In conjunction with the funding, Jonathan Silverstein of OrbiMed has been appointed to Rhythm Metabolic’s board of directors. Rhythm Metabolic is focused on treating obesity caused by genetic deficiencies.

VC-backed Kala taps Iwicki as executive chairman

Waltham, Massachusetts-based Kala Pharmaceuticals, a developer of treatments for ocular diseases, has named Mark Iwicki as executive chairman and a member of its board of directors. Previously, Iwicki was the president and CEO of Civitas Therapeutics Inc. Kala’s backers include Crown Venture Fund, Lux Capital, Polaris Partners, Third Rock Ventures and Ysios Capital.

CytomX grabs $20 mln Series C

Biotech firm CytomX has received $20 million in Series C financing. Pfizer Venture Investments led the round with participation from previous backers Third Rock Ventures, Canaan Partners and the Roche Venture Fund. In addition to the funding, Dr. Elaine Jones, executive director of venture capital at Pfizer Venture Investments, has been added to CytomX’s board of directors. Her appointment becomes effective January 15, 2015.

Allena Pharma raises $25 mln

Allena Pharmaceuticals has completed a $25 million Series B financing led by HBM Partners. Existing investors Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners and new investor Pharmstandard International also participated. Newton, Mass.-based Allena is specialty biopharmaceutical company that develops non-systemic protein therapeutics to treat metabolic and orphan diseases.


Blueprint Medicines ropes in $50 mln

Blueprint Medicines has raised $50 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments, Redmile Group, Fidelity Biosciences and Third Rock Ventures. Based in Cambridge, Mass., Blueprint Medicines is a developer of kinase inhibitors for genomically defined cancers.


VC-backed Rhythm files for IPO

Rhythm has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Citigroup and Cowen and Company are serving as the lead underwriters. Based in Boston, Rhythm is a biopharmaceutical firm that focuses on treating metabolic disorders. Its backers include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen and Pfizer Ventures.

VC-backed Jounce Therapeutics names new CEO

Jounce Therapeutics, which is backed by Third Rock Ventures, has hired Dr. Richard Murray as CEO. Murray is replacing interim CEO Dr. Cary Pfeffer, a partner at Third Rock Ventures, who will become chairman of Jounce’s board of directors. Previously, Murray worked at Merck where he recently served as senior vice president of biologics and vaccines research and was a member of the Merck Research Laboratories leadership team. Based in Cambridge, Mass., Jounce Therapeutics is focused on discovering and developing cancer immunotherapies.

DC Devices picks up $34 mln Series D

DC Devices, a medical device firm focused on treating heart failure, has secured $34 million in Series D funding. Accelmed led the round with participation from investors that included Third Rock Ventures, General Catalyst Partners and Lumira Capital.

VC-backed Editas Medicine hires CEO

Editas Medicine has hired Katrine S. Bosley as CEO. Previously, Bosley worked at Avila Therapeutics where she served as CEO. Based in Cambridge, Mass., Editas Medicine is a transformative genome editing firm. It is backed by Flagship Ventures, Polaris Partners, Third Rock Ventures and Partners Innovation Fund.

VC-backed Solstice Biologics hires new president/CEO and CFO

San Diego-based biotech startup Solstice Biologics, which is backed by venBio and Aeris Capital, has hired Dr. Lou Tartaglia as president and CEO. Tartaglia has also been added to the firm’s board of directors. Also, the firm has named John Borgeson as chief financial officer. Previously, Tartaglia worked at Third Rock Ventures where he was a partner while Borgeson was vice president of finance for Pfizer‘s biotherapeutic and bioinnovation center.


Nurix launches with Series B

Third Rock Ventures and The Column Group have backed the launch of Nurix with a $25.1 million Series B financing. Nurix develops therapies that modulate the ubiquitin proteasome system.

Kala Pharmaceuticals scores $22.5 mln

Kala Pharmaceuticals said Wednesday that it has closed $22.5 million in Series B financing. Ysios Capital led the round with participation from Crown Venture Fund, Lux Capital, Polaris Partners and Third Rock Ventures. In addition to the funding, Dr. Karen Wagner, a general partner at Ysios Capital, has been added to Kala’s board of directors. Based in Waltham, Mass., Kala Pharmaceuticals is a developer of treatments for ocular diseases.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget